Chordate Medical Holding - Public Comps and Valuation Multiples

Chordate Medical Holding Overview

About Chordate Medical Holding

Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company’s product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Founded

2005

HQ

Employees

Website

chordate.com

Sectors

Medical Devices
HealthTech

Financials

Last FY Revenue $0.1M

Last FY EBITDA -$2.6M

EV

$0.4M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Chordate Medical Holding Financials

In the most recent fiscal year, Chordate Medical Holding achieved revenue of $0.1M and an EBITDA of -$2.6M.

Chordate Medical Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Chordate Medical Holding valuation multiples based on analyst estimates

Chordate Medical Holding P&L

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$0.1M	XXX	XXX	XXX
Gross Profit	XXX	$0.2M	XXX	XXX	XXX
Gross Margin	XXX	299%	XXX	XXX	XXX
EBITDA	XXX	-$2.6M	XXX	XXX	XXX
EBITDA Margin	XXX	-3766%	XXX	XXX	XXX
EBIT	XXX	-$2.9M	XXX	XXX	XXX
EBIT Margin	XXX	-4129%	XXX	XXX	XXX
Net Profit	XXX	-$2.9M	XXX	XXX	XXX
Net Margin	XXX	-4100%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Chordate Medical Holding Stock Performance

As of July 17, 2025, Chordate Medical Holding's stock price is SEK 6 (or $1).

Chordate Medical Holding has current market cap of SEK 17.1M (or $1.8M), and EV of SEK 4.2M (or $0.4M).

See Chordate Medical Holding trading valuation data

Chordate Medical Holding Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$0.4M	$1.8M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Chordate Medical Holding Valuation Multiples

As of July 17, 2025, Chordate Medical Holding has market cap of $1.8M and EV of $0.4M.

Chordate Medical Holding's trades at 6.3x EV/Revenue multiple, and -0.2x EV/EBITDA.

Equity research analysts estimate Chordate Medical Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Chordate Medical Holding's P/E ratio is not available.

See valuation multiples for Chordate Medical Holding and 12K+ public comps

Chordate Medical Holding Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.8M	XXX	$1.8M	XXX	XXX	XXX
EV (current)	$0.4M	XXX	$0.4M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	6.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-0.2x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-0.2x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-0.6x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-0.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Chordate Medical Holding Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Chordate Medical Holding Margins & Growth Rates

Chordate Medical Holding's revenue per employee in the last FY averaged $23K, while opex per employee averaged $1.0M for the same period.

Chordate Medical Holding's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chordate Medical Holding's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Chordate Medical Holding and other 12K+ public comps

Chordate Medical Holding Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-3766%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$23K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	4428%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial